Alnylam Pharmaceuticals Inc. (ALNY)

89.76
0.60 0.67
NASDAQ : Health Technology
Prev Close 89.16
Open 88.81
Day Low/High 88.81 / 91.59
52 Wk Low/High 60.27 / 96.08
Volume 677.63K
Avg Volume 696.60K
Exchange NASDAQ
Shares Outstanding 111.21M
Market Cap 9.43B
EPS -7.60
P/E Ratio N/A
Div & Yield N.A. (N.A)
Alnylam Presents New Pre-clinical Data On ALN-AT3, An RNAi Therapeutic Targeting Antithrombin (AT) For The Treatment Of Hemophilia And Rare Bleeding Disorders (RBD)

Alnylam Presents New Pre-clinical Data On ALN-AT3, An RNAi Therapeutic Targeting Antithrombin (AT) For The Treatment Of Hemophilia And Rare Bleeding Disorders (RBD)

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, announced today that it has presented new pre-clinical data with ALN-AT3, a subcutaneously administered RNAi therapeutic targeting ...

New Alnylam Pre-clinical Results On ALN-CC5, An RNAi Therapeutic Targeting Complement Component C5 For The Treatment Of Complement-Mediated Diseases, Demonstrate Up To 98% Serum C5 Knockdown And Up To 94% Inhibition Of Hemolytic Activity In Non-Human Primates

New Alnylam Pre-clinical Results On ALN-CC5, An RNAi Therapeutic Targeting Complement Component C5 For The Treatment Of Complement-Mediated Diseases, Demonstrate Up To 98% Serum C5 Knockdown And Up To 94% Inhibition Of Hemolytic Activity In Non-Human Primates

Alnylam Pharmaceuticals, Inc. (Nasdaq:ALNY), a leading RNAi therapeutics company, announced today that it has presented new pre-clinical data with ALN-CC5, a subcutaneously administered RNAi therapeutic targeting ...

Best Biotech CEO of 2013: Your Vote Counts

Best Biotech CEO of 2013: Your Vote Counts

The CEOs from NPS Pharma, Onyx Pharma, Bristol-Myers Squibb, Celgene and Ligand Pharma vie for the coveted title of Best Biotech CEO.

Today's Stocks Driving Success For The Drugs Industry

Today's Stocks Driving Success For The Drugs Industry

TheStreet highlights 3 stocks pushing the drugs industry higher today.

Alnylam To Webcast Presentation At Upcoming Investor Conferences

Alnylam To Webcast Presentation At Upcoming Investor Conferences

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, today announced that management will present a company overview at the 2013 Deutsche Bank BioFEST on Monday, December 2, 2013 at 7:50...

(Photo: Business Wire)

(Photo: Business Wire)

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, announced today that it has earned a $7 million milestone from its partner Genzyme, a Sanofi company, for achieving Phase II success ...

First Week Of ALNY January 2014 Options Trading

First Week Of ALNY January 2014 Options Trading

Investors in Alnylam Pharmaceuticals Inc saw new options become available this week, for the January 2014 expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ALNY options chain for the new January 2014 contracts and identified one put and one call contract of particular interest.

Alnylam Presents New Pre-clinical Data On RNAi Therapeutics For Cardiovascular Disease At American Heart Association Meeting

Alnylam Presents New Pre-clinical Data On RNAi Therapeutics For Cardiovascular Disease At American Heart Association Meeting

Alnylam Pharmaceuticals, Inc. (Nasdaq:ALNY), a leading RNAi therapeutics company, announced today that it has presented new pre-clinical data from two RNAi therapeutic programs for cardiovascular disease, ...

Alnylam Pharmaceuticals Larger Than S&P 500 Component Teradyne

Alnylam Pharmaceuticals Larger Than S&P 500 Component Teradyne

In the latest look at stocks ordered by largest market capitalization, Russell 3000 component Alnylam Pharmaceuticals Inc was identified as having a larger market cap than the smaller end of the S&P 500, for example Teradyne, Inc. , according to The Online Investor.

Alnylam Receives Fast Track Designation For Patisiran (ALN-TTR02), An RNAi Therapeutic Targeting Transthyretin (TTR) For The Treatment Of TTR-Mediated Amyloidosis (ATTR)

Alnylam Receives Fast Track Designation For Patisiran (ALN-TTR02), An RNAi Therapeutic Targeting Transthyretin (TTR) For The Treatment Of TTR-Mediated Amyloidosis (ATTR)

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, announced today that the U.

Alnylam Reports Positive Phase II Data For Patisiran (ALN-TTR02), An RNAi Therapeutic Targeting Transthyretin (TTR) For The Treatment Of TTR-Mediated Amyloidosis (ATTR), And Initiates Phase III Trial

Alnylam Reports Positive Phase II Data For Patisiran (ALN-TTR02), An RNAi Therapeutic Targeting Transthyretin (TTR) For The Treatment Of TTR-Mediated Amyloidosis (ATTR), And Initiates Phase III Trial

Alnylam Pharmaceuticals, Inc. (Nasdaq:ALNY), a leading RNAi therapeutics company, announced today the achievement of positive clinical results from its Phase II trial of patisiran (ALN-TTR02), an RNAi therapeutic ...

Alnylam To Present New Pre-clinical Data On Multiple RNAi Therapeutic Programs At 55th Annual Meeting Of The American Society Of Hematology (ASH)

Alnylam To Present New Pre-clinical Data On Multiple RNAi Therapeutic Programs At 55th Annual Meeting Of The American Society Of Hematology (ASH)

Alnylam Pharmaceuticals, Inc. (Nasdaq:ALNY), a leading RNAi therapeutics company, announced today that it will present new pre-clinical data from its ALN-AT3, ALN-CC5, and ALN-TMP programs at the 55 th Annual ...

Alnylam Pharmaceuticals Reports Third Quarter 2013 Financial Results

Alnylam Pharmaceuticals Reports Third Quarter 2013 Financial Results

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, today reported its consolidated financial results for the third quarter 2013, and company highlights.

Alnylam Presents New Pre-clinical Data On ALN-AAT, An RNAi Therapeutic Targeting Alpha-1-Antitrypsin (AAT) For The Treatment Of AAT Deficiency Liver Disease

Alnylam Presents New Pre-clinical Data On ALN-AAT, An RNAi Therapeutic Targeting Alpha-1-Antitrypsin (AAT) For The Treatment Of AAT Deficiency Liver Disease

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, announced today that it has presented new pre-clinical data with ALN-AAT, an RNAi therapeutic targeting alpha-1 antitrypsin (AAT) in ...

Alnylam To Webcast Conference Call Discussing Third Quarter 2013 Financial Results

Alnylam To Webcast Conference Call Discussing Third Quarter 2013 Financial Results

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, today announced that it will report financial results for the third quarter ending September 30, 2013 on Wednesday, November 6, 2013,...

Alnylam Files Clinical Trial Application To Initiate A Phase I Study For ALN-AT3, A Subcutaneously Administered RNAi Therapeutic Targeting Antithrombin (AT) For The Treatment Of Hemophilia A And B

Alnylam Files Clinical Trial Application To Initiate A Phase I Study For ALN-AT3, A Subcutaneously Administered RNAi Therapeutic Targeting Antithrombin (AT) For The Treatment Of Hemophilia A And B

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, announced today that it has filed a Clinical Trial Application (CTA) with the U.

Alnylam Pharmaceuticals Stock Sees Short Interest Decline 12.6%

Alnylam Pharmaceuticals Stock Sees Short Interest Decline 12.6%

The most recent short interest data has been released by the NASDAQ for the 10/15/2013 settlement date, which shows a 473,780 share decrease in total short interest for Alnylam Pharmaceuticals Inc , to 3,300,814, a decrease of 12.55% since 09/30/2013. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded.

First Week Of June 2014 Options Trading For Alnylam Pharmaceuticals (ALNY)

First Week Of June 2014 Options Trading For Alnylam Pharmaceuticals (ALNY)

Investors in Alnylam Pharmaceuticals Inc saw new options begin trading this week, for the June 2014 expiration. One of the key data points that goes into the price an option buyer is willing to pay, is the time value, so with 241 days until expiration the newly trading contracts represent a possible opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.

The Medicines Company And Alnylam Advance Development Candidate For ALN-PCSsc, A Subcutaneously Administered RNAi Therapeutic Targeting PCSK9 Under Investigation For The Treatment Of Hypercholesterolemia

The Medicines Company And Alnylam Advance Development Candidate For ALN-PCSsc, A Subcutaneously Administered RNAi Therapeutic Targeting PCSK9 Under Investigation For The Treatment Of Hypercholesterolemia

The Medicines Company (Nasdaq: MDCO) a leading acute/intensive hospital care company, and Alnylam Pharmaceuticals, Inc.

Alnylam Advances Development Candidate For ALN-AS1, A Subcutaneously Administered RNAi Therapeutic Targeting Aminolevulinate Synthase 1 (ALAS-1) For The Treatment Of Hepatic Porphyrias

Alnylam Advances Development Candidate For ALN-AS1, A Subcutaneously Administered RNAi Therapeutic Targeting Aminolevulinate Synthase 1 (ALAS-1) For The Treatment Of Hepatic Porphyrias

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, announced today that it is advancing its Development Candidate for ALN-AS1, an RNAi therapeutic targeting aminolevulinate synthase-1 ...

Alnylam And Collaborators Publish Clinical Trial Results With ALN-PCS, An RNAi Therapeutic Targeting PCSK9 For The Treatment Of Hypercholesterolemia, In The Lancet

Alnylam And Collaborators Publish Clinical Trial Results With ALN-PCS, An RNAi Therapeutic Targeting PCSK9 For The Treatment Of Hypercholesterolemia, In The Lancet

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, announced today the publication in The Lancet of complete study results from a Phase I trial with ALN-PCS, a systemically ...

Alnylam Completes Enrollment Of Phase II Clinical Trial And Initiates Open-Label Extension (OLE) Study With ALN-TTR02, An RNAi Therapeutic Targeting Transthyretin (TTR) For The Treatment Of Transthyretin-Mediated Amyloidosis (ATTR)

Alnylam Completes Enrollment Of Phase II Clinical Trial And Initiates Open-Label Extension (OLE) Study With ALN-TTR02, An RNAi Therapeutic Targeting Transthyretin (TTR) For The Treatment Of Transthyretin-Mediated Amyloidosis (ATTR)

Alnylam Pharmaceuticals, Inc. (Nasdaq:ALNY), a leading RNAi therapeutics company, announced today that it has completed enrollment in its Phase II trial with ALN-TTR02, an RNAi therapeutic targeting the transthyretin...

Alnylam To Webcast Presentation At Leerink Swann Rare Disease Roundtable

Alnylam To Webcast Presentation At Leerink Swann Rare Disease Roundtable

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, today announced that management will present a company overview at the Leerink Swann Rare Disease Roundtable on Wednesday, October 2,...

Trading Stocks, Not the Market

Trading Stocks, Not the Market

While the broad indices have stalled, these names are breaking out.

Alnylam Reports Positive Clinical Results – With Up To 94% Knockdown Of Serum Transthyretin (TTR) – For ALN-TTRsc, A Subcutaneously Delivered RNAi Therapeutic For The Treatment Of TTR-Mediated Amyloidosis (ATTR)

Alnylam Reports Positive Clinical Results – With Up To 94% Knockdown Of Serum Transthyretin (TTR) – For ALN-TTRsc, A Subcutaneously Delivered RNAi Therapeutic For The Treatment Of TTR-Mediated Amyloidosis (ATTR)

Alnylam Pharmaceuticals, Inc. (Nasdaq:ALNY), a leading RNAi therapeutics company, announced today positive interim results from its Phase I clinical trial of ALN-TTRsc, a subcutaneously delivered RNAi...

Alnylam To Webcast Presentation At 20th Annual NewsMakers In The Biotech Industry Conference

Alnylam To Webcast Presentation At 20th Annual NewsMakers In The Biotech Industry Conference

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, today announced that management will present a company overview at the 20 th Annual NewsMakers in the Biotech Industry ...

Alnylam To Webcast Presentation At Upcoming Investor Conferences

Alnylam To Webcast Presentation At Upcoming Investor Conferences

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, today announced that management will present a company overview at the Morgan Stanley Global Healthcare Conference on Tuesday,...

Alnylam And Collaborators Publish Clinical Trial Results With RNAi Therapeutics Targeting Transthyretin (TTR) For The Treatment Of TTR-Mediated Amyloidosis (ATTR) In The New England Journal Of Medicine

Alnylam And Collaborators Publish Clinical Trial Results With RNAi Therapeutics Targeting Transthyretin (TTR) For The Treatment Of TTR-Mediated Amyloidosis (ATTR) In The New England Journal Of Medicine

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, announced today the publication of complete study results from Phase I trials with ALN-TTR01 and ALN-TTR02 in the New England ...

Alnylam Receives Additional Orphan Drug Designation From U.S. Food & Drug Administration For ALN-AT3, An RNAi Therapeutic For The Treatment Of Hemophilia

Alnylam Receives Additional Orphan Drug Designation From U.S. Food & Drug Administration For ALN-AT3, An RNAi Therapeutic For The Treatment Of Hemophilia

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, announced today that the U.

Alnylam Receives Orphan Drug Designation From U.S. Food & Drug Administration For ALN-AT3, An RNAi Therapeutic For The Treatment Of Hemophilia

Alnylam Receives Orphan Drug Designation From U.S. Food & Drug Administration For ALN-AT3, An RNAi Therapeutic For The Treatment Of Hemophilia

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, announced today that the U.